Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery

Christopher G. Smith,1,* Daniel L. Davenport,2 Justin Gorski,1,3 Anthony McDowell,1,3 Brian T. Burgess,1,3 Tricia I. Fredericks,1,3 Lauren A. Baldwin,1,3 Rachel W. Miller,1,3 Christopher P. DeSimone,1,3 Charles S. Dietrich III,1,3 Holly H. Gallion,1,3 Edward J. Pavlik,1,3, John R. van Nagell Jr.,1,3 and Frederick R. Ueland1,3

1 Department of Obstetrics & Gynecology, University of Kentucky, Lexington, KY 40536-0293, USA
2 Department of Surgery, University of Kentucky, Lexington, KY 40536-0293, USA
3 Division of Gynecologic Oncology, Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0293, USA

* Correspondence: christophergsmith@uky.edu; Tel.: +1-(620)-481-7348

Received: 4 June 2019; Accepted: 24 June 2019; Published: 3 July 2019

Abstract: Background: Ovarian cancer (OC) is the leading cause of death from gynecologic malignancy and is treated with a combination of cytoreductive surgery and platinum-based chemotherapy. Extended length of stay (LOS) after surgery can affect patient morbidity, overall costs, and hospital resource utilization. The primary objective of this study was to identify factors contributing to prolonged LOS for women undergoing surgery for ovarian cancer.

Methods: The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database was queried to identify women from 2012–2016 who underwent hysterectomy for ovarian, fallopian tube and peritoneal cancer. The primary outcome was LOS >50th percentile. Preoperative and intraoperative variables were examined to determine which were associated with prolonged LOS.

Results: From 2012–2016, 1771 women underwent elective abdominal surgery for OC and were entered in the ACS-NSQIP database. The mean and median LOS was 4.6 and 4.0 days (IQR 0–38), respectively. On multivariate analysis, factors associated with prolonged LOS included: American Society of Anesthesiologists (ASA) Classification III (aOR 1.71, 95% CI 1.38–2.13) or IV (aOR 1.88, 95% CI 1.44–2.46), presence of ascites (aOR 1.88, 95% CI 1.44–2.46), older age (aOR 1.23, 95% CI 1.13–1.35), platelet count >400,000/mm3 (aOR 1.74, 95% CI 1.29–2.35), preoperative blood transfusion (aOR 11.00, 95% CI 1.28–94.77), disseminated cancer (aOR 1.28, 95% CI 1.03–1.60), increased length of operation (121–180 min, aOR 1.47, 95% CI 1.13–1.91; >180 min, aOR 2.78, 95% CI 2.13–3.64), and postoperative blood transfusion within 72 h of incision (aOR 2.04, 95% CI 1.59–2.62) (p < 0.05 for all).

Conclusions: Longer length of hospital stay following surgery for OC is associated with many patient, disease, and treatment-related factors. The extent of surgery, as evidenced by perioperative blood transfusion and length of surgical procedure, is a factor that can potentially be modified to shorten LOS, improve patient outcomes, and reduce hospital costs.

Keywords: ovarian cancer; length of stay; ACS-NSQIP; blood transfusion; neoadjuvant chemotherapy; interval debulking surgery; primary cytoreductive surgery

1. Introduction

Ovarian cancer (OC) is the leading cause of gynecological cancer death for women in the United States [1]. In 2018, there were roughly 22,000 new cases of ovarian cancer and 14,000 deaths [2]. Over sixty percent of women diagnosed with ovarian cancer have either Stage III or IV disease [3] and are treated with a combination of cytoreductive surgery and platinum-based chemotherapy [4]. Surgery for advanced stage cancer can be extensive and often results in longer hospitalizations [5].
Length of hospital stay (LOS) following surgical cancer care is an important measure of short-term quality of care. Prolonged LOS increases medical resource utilization, overall cost, readmissions, and short-term mortality \cite{6,7}. Longer hospitalizations are also associated with iatrogenic and hospital-acquired sequelae that contribute to increased morbidity and mortality \cite{8}. Preoperative hypoalbuminemia (albumin <3.5 g/dL), body weight loss (>10 percent decrease in body weight six months prior to surgery), body mass index <18.5 kg/m², dialysis status, disseminated cancer, increasing frailty, non-Caucasian race, perioperative anemia, blood transfusion, increasing operative time, age, and American Society of Anesthesiologists (ASA) classification have all been associated with prolonged LOS for various abdominal and gynecological surgeries \cite{9–17}.

The current literature is lacking regarding the perioperative factors affecting LOS for women undergoing surgery for ovarian cancer. The primary objective of this population-based quality assessment analysis is to understand the clinical factors associated with longer LOS following ovarian cancer surgery.

2. Materials and Methods

The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database was examined to identify patients who underwent surgery for ovarian, fallopian tube, and peritoneal cancer from 2012–2016.

The ACS-NSQIP database is a reporting system intended to provide reliable, risk-adjusted surgical outcomes data to surgical services and medical center administrators allowing the assessment and improvement of surgical quality at a national level. As previously reported, the ACS-NSQIP data are prospectively collected in a standardized fashion according to strict definitions by dedicated clinical data coordinators. Risk and outcome variables are meticulously defined, and coordinators complete in-depth training on all study definitions. Regular conference calls, annual meetings, and site visits are used to maintain data reliability. Patients are followed throughout their hospital stay and after hospital discharge up to 30 days postoperatively. Clinical data coordinators collect data from patients electronic and paper medical records, and patient telephone interviews. Additional operations within 30 days of an included case are excluded. Patients less than 18 years old and admissions for trauma are excluded. The accuracy and reproducibility of the data have been previously demonstrated \cite{18–21}.

Current Procedural Terminology (CPT®) codes were used to select patients from the ACS-NSQIP database who had undergone elective same-day surgery for ovarian, fallopian tube, and peritoneal cancers from 2012–2016 (Appendix A). International Classification of Diseases, 9th and 10th Revision (ICD-9, ICD-10) codes were used to identify patients with ovarian, fallopian tube, and peritoneal cancers, which will be collectively referred to in this manuscript as ovarian cancer (OC) (Appendix B).

Patient variables and complications were defined and abstracted according to the ACS-NSQIP methodology. Specifically, “disseminated malignancy” is defined by ACS-NSQIP as “patients who have cancer that: (1) Has spread to one site or more sites in addition to the primary site AND (2) in whom the presence of multiple metastases indicates the cancer is widespread, fulminant or near terminal.” “Ascites” is defined within the database as the presence of fluid accumulation in the peritoneal cavity noted on physical examination, abdominal ultrasound, or abdominal computed tomography (CT)/magnetic resonance imaging (MRI) within 30 days prior to surgery, or malignant ascites due to extensive cancer (excluding liver disease) \cite{18}.

For each patient, ACS-NSQIP collects LOS data which is defined as the length of hospitalization from the date of admission for elective same day surgery until discharge. Prolonged LOS was defined as LOS greater than the median.

Demographic, medical history, review of systems and laboratory values were compared between patients who had prolonged LOS and those who did not. Chi-square testing was performed for categorical variables, and Fisher’s exact tests were used for binary variables. Only variables with \( p < 0.05 \) for bivariate comparisons were included in the multivariable analysis. Stepwise logistic regression was used to determine independent risk factors for prolonged LOS. Significant risk factors identified in the bivariate analysis were considered for inclusion into the multivariate analysis if \( p < 0.05 \) and were removed from analysis if \( p > 0.10 \).
Once independent preoperative risks were determined, intraoperative variables were identified in a similar step forward fashion while adjusting for the presence of preoperative variables [22]. The Hosmer–Lemeshow statistic reflects results of the Hosmer–Lemeshow test which tests the goodness of fit for logistic regression and is primarily used in risk prediction models; small values reflect a poorly fit model. The concordance (c) statistic was calculated to measure discrimination of the multivariable model. The c-statistic has values ranging from 0–1 and represent the area under the receiver operating characteristic curve. Values close to 0.5 indicate a poor model, 0.7–0.8 as good, while those values near 1 reflect a strong model.

3. Results

The ACS-NSQIP database contained 1771 patients who underwent same day elective surgery for OC from 2012–2016. Laparotomy was performed in all cases. Mean and median LOS was 4.6 and 4.0 days (IQR 0–38), respectively. For this study, prolonged length of stay was defined as >4 days.

The results of a bivariate analysis are listed in Table 1. Several non-modifiable risk factors were associated with prolong LOS, including older age (63.5 vs. 60.2, \( p < 0.001 \)), American Society of Anesthesiologists (ASA) Classification III or IV (67.6% vs. 50.3%, \( p < 0.001 \)), elevated hepatic transaminases (5.9% vs. 3.5%, \( p = 0.006 \)), renal dysfunction (5.4% vs. 2.5%, \( p = 0.003 \)), ascites (24.2% vs. 12.5%, \( p < 0.001 \)), disseminated cancer (37.3% vs. 26.6%, \( p < 0.001 \)), and recent weight loss (5.9% vs. 3.7%, \( p = 0.04 \)). Other preoperative factors associated with longer LOS include blood transfusion (1.0% vs. 0.1%, \( p = 0.008 \)), hematocrit <38% (58.8% vs. 53.2%, \( p < 0.001 \)), and thrombocytosis (17.0% vs. 10.5%, \( p < 0.001 \)).

Intraoperative variables associated with prolonged postoperative LOS include blood transfusion within 72 h of incision (33.8% vs. 15.0%, \( p < 0.001 \)) and length of surgery (176 min vs. 146 min, \( p < 0.001 \)), particularly operative times exceeding 180 min (Table 1).

Table 1. Preoperative and intraoperative variables of patients undergoing surgery for ovarian cancer, stratified by length of stay. Median length of stay was 4 days.

| Variable                                | LOS 0–4 Days(s) (n = 1159) | LOS >4 Days (n = 612) | All Patients (n = 1771) | \( p \)-Value * |
|------------------------------------------|-----------------------------|------------------------|--------------------------|----------------|
| **Preoperative**                         |                             |                        |                          |                |
| Age, years (mean, standard deviation)    | 60.2 (11.9)                 | 63.5 (11.8)            | 61.3 (12.0)              | <0.001         |
| Body Mass Index >30 kg/m²                | 404 (34.9)                  | 235 (38.4)             | 639 (36.1)               | 0.145          |
| ASA Classification                       |                             |                        |                          |                |
| 1–2                                      | 577 (49.8)                  | 198 (32.4)             | 775 (43.8)               | <0.001         |
| 3                                        | 550 (47.5)                  | 377 (61.6)             | 927 (52.3)               |                |
| 4                                        | 32 (2.8)                    | 37 (6.0)               | 69 (3.9)                 |                |
| White Race                               |                             |                        |                          |                |
| Black                                    | 57 (4.9)                    | 47 (7.7)               | 104 (5.9)                |                |
| Other                                    | 77 (6.6)                    | 34 (5.6)               | 111 (6.3)                |                |
| Undocumented                             | 203 (17.5)                  | 81 (13.2)              | 284 (16.0)               |                |
| Hispanic Ethnicity                       |                             |                        |                          |                |
| Unknown                                  | 195 (16.8)                  | 68 (11.1)              | 263 (14.9)               |                |
| Not Hispanic                             | 902 (77.8)                  | 516 (84.3)             | 1418 (80.1)              |                |
| Diabetes, Non-insulin                    | 100 (8.6)                   | 65 (10.6)              | 165 (9.3)                | 0.059          |
| Insulin                                  | 38 (3.3)                    | 31 (5.1)               | 69 (3.9)                 |                |
| Dyspnea                                  | 72 (6.2)                    | 58 (9.5)               | 130 (7.3)                | 0.016          |
| Ascites                                  | 145 (12.5)                  | 148 (24.2)             | 293 (16.5)               | <0.001         |
| Disseminated Cancer                      | 308 (26.6)                  | 228 (37.3)             | 536 (30.3)               | <0.001         |
| Recent weight loss >10% body mass        | 43 (3.7)                    | 36 (5.9)               | 79 (4.5)                 | 0.040          |
| Treated hypertension                     | 461 (39.8)                  | 304 (49.7)             | 765 (43.2)               | <0.001         |
| Preoperative blood transfusion           | 1 (0.1)                     | 6 (1.0)                | 7 (0.4)                  | 0.008          |
| Preoperative SIRS/Septic Shock           | 8 (0.7)                     | 9 (1.5)                | 17 (1.0)                 | 0.126          |
| Alkaline Phosphatase >125 IU/L           | 55 (4.7)                    | 50 (8.2)               | 105 (5.9)                | 0.006          |
| SGOT >40 U/L                             | 41 (3.5)                    | 36 (5.9)               | 77 (4.3)                 | 0.027          |
| Creatinine >1.2 mg/dL                    | 29 (2.5)                    | 33 (5.4)               | 62 (3.5)                 | 0.003          |
| Hematocrit <38%                          | 617 (53.2)                  | 360 (58.8)             | 977 (55.2)               | 0.027          |
| Platelets >400,000/mL                    | 122 (10.5)                  | 104 (17.0)             | 226 (12.8)               | <0.001         |
| PTT >35 s                                | 45 (3.9)                    | 40 (6.5)               | 85 (4.8)                 | 0.019          |
Table 1. Cont.

| Variable                              | LOS 0–4 Day(s) (n = 1159) | LOS >4 Days (n = 612) | All Patients (n = 1771) | p-Value *
|---------------------------------------|---------------------------|-----------------------|-------------------------|---------
| Wound Classification                   |                           |                       |                         |         |
| 1-Clean                                | 69 (6.0)                  | 36 (5.9)              | 105 (5.9)               | 0.842   |
| 2-Clean/Contaminated                   | 1042 (89.9)               | 547 (89.4)            | 1589 (89.7)             |         |
| 3-Contaminated                         | 48 (4.1)                  | 29 (4.7)              | 77 (4.3)                |         |
| Duration of Operation, min. (mean, standard deviation) | 146 (67)                  | 176 (79)              | 156 (73)                | <0.001  |
| Transfusion within 72 h's. of incision | 174 (15.0)                | 207 (33.8)            | 381 (21.5)              | <0.001  |

* Fisher exact test or chi-square test. p < 0.05 was considered statistically significant; ASA—American Society of Anesthesiologists; SIRS—systemic inflammatory response syndrome; SGOT—Aspartate transaminase; IU—international units; PTT—partial thromboplastin time.

The findings from the multivariate analysis are summarized in Table 2. Preoperative clinical factors associated with prolonged LOS include ASA Class III (aOR 1.71, 95% CI 1.38–2.13), ASA Class IV (aOR 1.88, 95% CI 1.44–2.46), ascites (aOR 1.88, 95% CI 1.44–2.46), age (aOR 1.23, 95% CI 1.13–1.35), thrombocytosis (aOR 1.74, 95% CI 1.29–2.35), blood transfusion (aOR 11.00, 95% CI 1.28–94.77), and disseminated cancer (aOR 1.28, 95% CI 1.03–1.60). Other clinical factors associated with prolonged LOS include blood transfusion within 72 h of incision (aOR 2.04, 95% CI 1.59–2.62) and operative time >180 min (aOR 2.78, 95% CI 2.13–3.64). The multivariable model showed goodness of fit (Hosmer–Lemeshow statistic $p = 0.398$), as well as good discrimination of patients with prolonged LOS after surgery for ovarian cancer (c-statistic = 0.71, 95% CI = 0.69–0.74).

Table 2. Multivariable predictors of prolonged LOS in patients undergoing hysterectomy for ovarian cancer (Hosmer-Lemeshow (H-L) statistic $p = 0.398$, c-index = 0.71).

| Variable                              | Prevalence (%) | Adjusted Odds Ratio (95% CI) | p-Value *
|---------------------------------------|----------------|-------------------------------|---------|
| Age per 10 years from mean            | 63.5 (11.8)    | 1.23 (1.13–1.35)              | <0.001  |
| ASA Classification III vs. I-II (ref.)| 377 (61.6)     | 1.71 (1.38–2.13)              | <0.001  |
| IV                                    | 37 (6.0)       | 2.80 (1.68–4.66)              | <0.001  |
| Ascites                               | 148 (24.2)     | 1.88 (1.44–2.46)              | <0.001  |
| Platelets >400,000/mL                 | 104 (17.0)     | 1.74 (1.29–2.35)              | <0.001  |
| Preoperative blood transfusion        | 6 (1.0)        | 11.00 (1.28–94.77)            | 0.029   |
| Disseminated cancer                   | 56 (37.3)      | 1.28 (1.03–1.60)              | 0.028   |
| Duration of Operation (mins)          |                |                               |         |
| ≤120 vs. 121–180 (ref)                | 200 (32.7)     | 1.47 (1.13–1.91)              | 0.004   |
| >180                                  | 257 (42.0)     | 2.78 (2.13–3.64)              | <0.001  |
| Transfusion within 72 hrs. of incision| 207 (33.8)     | 2.04 (1.59–2.62)              | <0.001  |

* Fisher exact test or chi-square test. p < 0.05 was considered statistically significant; ASA—American Society of Anesthesiologists.

4. Discussion

Our investigation has identified an association between longer LOS and several clinical factors following surgery for ovarian cancer, some of which can be potentially impacted by medical or surgical decisions. OC is a disease of older women who frequently have numerous medical comorbidities like hypertension, diabetes mellitus, cardiovascular disease, and pulmonary disease [23,24]. Women generally present with advanced and disseminated cancer which is commonly associated with weight loss, severe malnutrition, and impaired gastrointestinal function, which can contribute to a protracted surgical recovery, and prolonged hospitalization [25]. Women with advanced stage disease typically undergo extensive cytoreductive surgery resulting in longer hospitalizations [3].
The extent of ovarian cancer surgery correlates with length of surgery, blood loss, and transfusion rate which we demonstrated to predict prolonged LOS (Table 2) [15,26,27]. Neoadjuvant chemotherapy (NACT), comprising of three (sometimes 4–6) cycles of platinum-based chemotherapy followed by interval debulking surgery (IDS) [5], is a compelling treatment approach that can impact some of these controllable risk factors. Two recent randomized, controlled trials found equivalent overall survival and progression-free survival (30 vs. 29 months; 24.1 vs. 22.6 months (overall survival), 12 months; 10.7 vs. 12.0 months (progression-free survival)) with reduced surgical morbidity following NACT with interval debulking surgery (IDS) compared to PCS with the goal of both surgeries to resect all visible disease [28,29]. A recent meta-analysis comparing NACT to primary cytoreductive surgery (PCS) reported that NACT had a higher rate of complete cytoreduction (RR 1.95 (95% CI 1.33–2.87)), less perioperative infection (RR 0.30 (95% CI 0.16–0.56)), fewer gastrointestinal fistulae (RR 0.24 (95% CI 0.06–0.95)), fewer grade 3 or 4 adverse events (RR 0.29 (95% CI 0.11–0.78)), fewer postsurgical deaths (RR 0.14 (95% CI 0.04–0.49)), and better quality of life [30]. Furthermore, NACT has been shown to have decreased intraoperative blood losses, is less likely to receive perioperative blood transfusions with decreased number of units received, has earlier times to ambulation and return of intestinal function, and has shorter LOS [28,29,31–34]. NACT is also associated with significantly fewer intestinal diversions (10.8% vs. 23.3%, p < 0.0001) [35]. NACT is becoming increasingly common in the United States as quality and safety data continues to favor NACT over PCS [36]. Additionally, NACT is utilized more for women with high perioperative risk or unresectable disease, common characteristics of patients with OC [4,37].

Admission to an intensive care unit (ICU) is needed for 25–36% of women undergoing aggressive PCS for ovarian cancer [38]. Factors associated with ICU admission following surgery for a gynecologic cancer include many of the factors identified in this investigation relating to LOS, including advanced age, medical comorbidities, malnutrition, long operative times, blood loss and blood transfusions, as well as increased intraoperative fluid resuscitation and bowel resection with anastomosis [39,40]. PCS results in a nearly three-fold increase in ICU admissions and longer LOS when compared to NACT. Even though patients receiving NACT are generally older and have more advanced disease, ICU admission rates are significantly lower compared to PCS. Patient survival is also worse following unplanned ICU admissions, including a shorter median survival (27.3 vs. 57.9 months, p < 0.001, adjusted HR 2.16, 95% CI 1.53–3.05). The increased utilization of NACT will likely reduce the length and number of ICU admissions for women undergoing ovarian cancer surgery, while also decreasing overall LOS [5].

Patient morbidity and mortality are not the only considerations related to prolonged LOS following surgery for OC. It is well known that prolonged LOS contributes to increased cost for both patient and hospital [40,41]. Pragmatically, when LOS is shorter than the national average, the Medicare payment to the hospital is likely to exceed the actual cost of care. Thus, patients and hospitals both stand to benefit from shorter LOS [42,43].

This investigation has several strengths. The database identified a large cohort of women undergoing surgery for ovarian cancer. The data is prospectively collected from a well-established national database, and it is generalizable since it was collected from numerous medical facilities. Unfortunately, information for NACT was not included in the study because of insufficient numbers in the NSQIP database. Also, cancer stage and histology are variables not included in the NSQIP database, therefore specific stage and histology information is not provided in this manuscript. Additionally, the volume of blood loss, immediate pre- and postoperative hemoglobin/hematocrit concentrations, as well as the thresholds utilized for blood transfusion are not available for analysis. Other factors that may influence perioperative outcomes such as operating surgeon experience, surgical volume, and institution type are not able to be controlled using the ACS-NSQIP database but does lend to the generalizability of the findings. Furthermore, the study period for which hysterectomy data was available was before the publication of ERAS Pathways for gynecologic oncology surgery. As with all retrospective studies, information and selection biases may affect comparisons.
5. Conclusions

Our findings identify several important variables that are associated with longer hospitalizations following surgery for ovarian cancer. Older, sicker patients with clinical findings of advanced cancer, who undergo complex surgery (demonstrated by increased likelihood of blood transfusion, and longer surgeries), have a greater association with longer hospitalizations (Table 2). Some of these clinical factors can potentially be influenced by treatment-related decisions, specifically the extent of surgery, the surgical procedure itself, and possibly NACT. In the future, the increased use of the ACS-NSQIP database by gynecologic oncologists should allow for meaningful comparisons between PCS and NACT.

Author Contributions: Conceptualization, C.G.S.; Data curation, D.L.D.; Formal analysis, D.L.D.; Supervision, J.R.v.N.J. and F.R.U.; Writing—original draft, C.G.S. and F.R.U.; Writing—review & editing, C.G.S., J.G., A.McD., B.T.B., T.I.F., L.A.B., R.W.M., C.P.D., C.S.D.III, H.H.G., E.J.P., J.R.v.N.J. and F.R.U.

Funding: This research received no external funding.

Acknowledgments: The American College of Surgeons National Surgical Quality Improvement Program and the hospitals participating in the ACS NSQIP are the source of the data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

Conflicts of Interest: The authors whose names are listed above declare that they have NO affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript. The authors declare no conflict of interest.

Appendix A

| Table A1. Primary current procedure terminology codes included in the study. |
|---------------------------------|
| **Primary CPT® Codes of Procedures Included in Study** |
| 58951 | Total abdominal hysterectomy/bilateral salpingo-oophorectomy, debulking, lymph node dissection |
| 58953 | Total abdominal hysterectomy/bilateral salpingo-oophorectomy, radical debulking |
| 58954 | Bilateral salpingo-oophorectomy with omentectomy, total abdominal hysterectomy and radical dissection for debulking; with pelvic lymphadenectomy and limited para-aortic lymphadenectomy |
| 58956 | Total abdominal hysterectomy/bilateral salpingo-oophorectomy, omentectomy |
| 58957 | Total abdominal hysterectomy/bilateral salpingo-oophorectomy, +/- omentectomy |
| 58150 | Total abdominal hysterectomy (corpus and cervix), with or without removal of tube(s), with or without removal of ovary(s) |

Appendix B

| Table A2. International statistical classification of diseases and related health problems codes included in the study. |
|---------------------------------|
| **ICD-9 Codes Included in Study** |
| 158.8 | Malignant neoplasm of specified parts of peritoneum |
| 158.9 | Malignant neoplasm of peritoneum, unspecified |
| 183.0 | Malignant neoplasm of ovary |
| 183.2 | Malignant neoplasm of fallopian tube |
| 183.3 | Malignant neoplasm of broad ligament of uterus |
| 183.4 | Malignant neoplasm of parametrium |
| 183.8 | Malignant neoplasm of other specified sites of uterine adnexa |
| 183.9 | Malignant neoplasm of uterine adnexa, unspecified site |
| **ICD-10 Codes included in study** |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C56 | Malignant neoplasm of ovary |
| C57 | Malignant neoplasm of other and unspecified female genital organs |
| C57.4 | Malignant neoplasm of uterine adnexa, unspecified |
| D39.1 | Neoplasm of uncertain behavior of ovary |
| D39.11 | Neoplasm of uncertain behavior of right ovary |
| D39.12 | Neoplasm of uncertain behavior of left ovary |
References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2019. *Ca A Cancer J. Clin.* 2019, 69, 7–34. [CrossRef] [PubMed]

2. Howlader, N.; Noone, A.M.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Altekruse, S.F.; Kosary, C.L.; Ruhl, J.; Tatalovich, Z.; et al. *Surveillance, Epidemiology, and End Results Program*; National Cancer Institute: Bethesda, Rockville, MD, USA, 1986. Available online: https://seer.cancer.gov/statfacts/html/ovary.html (accessed on 20 September 2018).

3. Torre, L.A.; Trabert, B.; DeSantis, C.E.; Miller, K.D.; Samimi, G.; Runowicz, C.D.; Gaudet, M.M.; Jemal, A.; Siegel, R.L. Ovarian Cancer Statistics. *Ca: A Cancer J. Clin.* 2018, 68, 284–296. [CrossRef] [PubMed]

4. National Comprehensive Cancer Network. *Ovarian Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology*; National Comprehensive Cancer Network: Cleveland, OH, USA, 1995.

5. Ross, M.S.; Burriss, M.E.; Winger, D.G.; Edwards, R.P.; Courtney-Brooks, M.; Boisen, M.M. Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival. *Gynecol. Oncol.* 2018, 150, 306–310. [CrossRef] [PubMed]

6. Chiu, H.-C.; Lin, Y.-C.; Hsieh, H.-M.; Chen, H.-P.; Wang, H.-L.; Wang, J.-Y. The impact of complications on prolonged length of hospital stay after resection in colorectal cancer: A retrospective study of Taiwanese patients. *J. Int. Med. Res.* 2017, 45, 691–705. [CrossRef] [PubMed]

7. Brasel, K.J.; Lim, H.J.; Nirula, R.; Weigelt, J.A. Length of stay: An appropriate quality measure? *Arch. Surg.* 2007, 142, 461–465. [CrossRef] [PubMed]

8. Caminiti, C.; Meschi, T.; Braglia, L.; Diodati, F.; Iezzi, E.; Marcomini, B.; Nouvenne, A.; Palermo, E.; Prati, B.; Schianchi, T.; et al. Reducing unnecessary hospital days to improve quality of care through physician accountability: A cluster randomized trial. *BMC Health Serv. Res.* 2013, 13, 14. [CrossRef] [PubMed]

9. Hu, W.H.; Cajas-Monson, L.C.; Eisenstein, S.; Parry, L.; Cosman, B.; Ramamoorthy, S. Preoperative malnutrition assessments as predictors of postoperative mortality and morbidity in colorectal cancer: An analysis of ACS-NSQIP. *Nutr. J.* 2015, 14, 91. [CrossRef]

10. Hu, W.H.; Cajas-Monson, L.C.; Eisenstein, S.; Parry, L.; Cosman, B.; Ramamoorthy, S. Association of dialysis with adverse postoperative outcomes in colorectal cancer—an analysis of ACS-NSQIP. *Int. J. Colorectal Dis.* 2015, 30, 1557–1562. [CrossRef]

11. Bateni, S.B.; Meyers, F.J.; Bold, R.J.; Canter, R.J. Increased Rates of Prolonged Length of Stay, Readmissions, and Discharge to Care Facilities among Postoperative Patients with Disseminated Malignancy: Implications for Clinical Practice. *PLoS ONE* 2016, 11, e0165315. [CrossRef]

12. Leeds, I.L.; Canner, J.K.; Efron, J.E.; Ahuja, N.; Haur, E.R.; Wick, E.C.; Johnston, F.M. The independent effect of cancer on outcomes: A potential limitation of surgical risk prediction. *J. Surg. Res.* 2017, 220, 402–409. [CrossRef]

13. Vermillion, S.A.; Hsu, F.C.; Dorrell, R.D.; Shen, P.; Clark, C.J. Modified frailty index predicts postoperative outcomes in older gastrointestinal cancer patients. *J. Surg. Oncol.* 2017, 115, 997–1003. [CrossRef] [PubMed]

14. Mahdi, H.; Jernigan, A.; Lockhart, D.; Moslemi-Kebria, M.; Rose, P.G. Racial disparity in 30-day morbidity and mortality after surgery for ovarian cancer. *Int. J. Gynecol. Cancer* 2015, 25, 55–62. [CrossRef] [PubMed]

15. Prescott, L.S.; Aloia, T.A.; Brown, A.J.; Taylor, J.S.; Munsell, M.F.; Sun, C.C.; Schmeler, K.M.; Levenback, C.F.; Bodurka, D.C. Perioperative blood transfusion in gynecologic oncology surgery: Analysis of the National Surgical Quality Improvement Program Database. *Gynecol. Oncol.* 2015, 136, 65–70. [CrossRef] [PubMed]

16. Dunne, J.R.; Malone, D.; Tracy, J.K.; Gannon, C.; Napolitano, L.M. Perioperative anemia: An independent risk factor for infection, mortality, and resource utilization in surgery. *J. Surg. Res.* 2002, 102, 237–244. [CrossRef] [PubMed]

17. Xourafas, D.; Pawlik, T.M.; Cloyd, J.M. Independent Predictors of Increased Operative Time and Hospital Length of Stay Are Consistent Across Different Surgical Approaches to Pancreatoduodenectomy. *J. Gastrointest. Surg.* 2018, 22, 1911–1919. [CrossRef]

18. American College of Surgeons. *User Guide for the 2016 ACS NSQIP Participant Use Data File (PUF)*; American College of Surgeons: Chicago, IL, USA, 2017; Available online: https://www.facs.org/~ingegenius/quality%20programs/nsqip/nsqip_puf_userguide_2016.ashx (accessed on 20 September 2018).
19. Khuri, S.F.; Daley, J.; Henderson, W.; Hur, K.; Damkis, J.; Aust, J.B. The Department of Veterans Affairs' NSQIP: The first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. *Ann. Surg.* 1998, 228, 491–507. [CrossRef]

20. Daley, J.; Khuri, S.F.; Henderson, W.; Hur, K.; Gibbs, J.O.; Barbour, G. Risk adjustment of the postoperative morbidity rate for the comparative assessment of the quality of surgical care: Results of the National Veterans Affairs Surgical Risk Study. *J. Am. Coll. Surg.* 1997, 185, 328–340. [CrossRef]

21. Khuri, S.F.; Daley, J.; Henderson, W.; Hur, K.; Gibbs, J.O.; Barbour, G. Risk adjustment of the postoperative mortality rate for the comparative assessment of the quality of surgical care: Results of the National Veterans Affairs Surgical Risk Study. *J. Am. Coll. Surg.* 1997, 185, 315–327.

22. Moreno Elola-Olaso, A.; Davenport, D.L.; Hundley, J.C.; Daily, M.F.; Gedaly, R. Predictors of surgical site infection after liver resection: A multicenter analysis using National Surgical Quality Improvement Program data. *HPB* 2012, 12, 136–141. [CrossRef]

23. Chakalova, G. Management of gynecological cancer patients older than 70 years of age. *Int. J. Gerontol.* 2015, 9, 93–97. [CrossRef]

24. Jørgensen, T.L.; Teiblum, S.; Paludan, M.; Poulsen, L.O.; Young, A.; Jørgensen, S.; Bruun, K.H.; Herrstedt, J. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. *Gynecol. Oncol.* 2012, 127, 367–374. [CrossRef] [PubMed]

25. Pin, F.; Barreto, R.; Kitase, Y.; Mitra, S.; Erne, C.E.; Novinger, L.J.; Zimmers, T.A.; Couch, M.E.; Bonevald, L.F.; Bonetto, A. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. *J. Cachexia Sarcopenia Muscle* 2018, 9, 685–700. [CrossRef] [PubMed]

26. Cheng, H.; Po-Han Chen, B.; Soleas, I.M.; Ferko, N.C.; Cameron, C.G.; Hinoul, P. Prolonged Operative Duration Increases Risk of Surgical Site Infections: A Systematic Review. *Surg. Infect.* 2017, 18, 722–735. [CrossRef]

27. Warner, L.L.; Dowdy, S.C.; Martin, J.R.; Lemens, M.A.; McGree, M.E.; Weaver, A.L.; Podratz, K.C.; Bakkum-Gamez, J.N. The Impact of Perioperative Packed Red Blood Cell Transfusion on Survival in Epithelial Ovarian Cancer. *Int. J. Gynecol. Cancer* 2013, 23, 1612–1619. [CrossRef]

28. Vergote, I.; Trope, C.G.; Amant, F.; Kristensen, G.B.; Ehlen, T.; Johnson, N.; Verheijen, R.H.; van der Burg, M.E.; Lacave, A.J.; Panici, P.B.; et al. Neoadjuvant chemotherapy or primary surgery in stage IIIIC or IV ovarian cancer. *N. Engl. J. Med.* 2010, 363, 943–953. [CrossRef] [PubMed]

29. Kehoe, S.; Hook, J.; Nankivell, M.; Jayson, G.C.; Kitchener, H.; Lopes, T.; Luesley, D.; Perren, T.; Bannoo, S.; Mascarenhas, M.; et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. *Lancet.* 2015, 386, 249–257. [CrossRef] [PubMed]

30. Yang, L.; Zhang, B.; Xing, G.; Du, J.; Yang, B.; Yuan, Q.; Yang, Y. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome. *PLoS One* 2017, 12, e0186725. [CrossRef]

31. Fagotti, A.; Ferrandina, G.; Vizzieri, G.; Fanfani, F.; Gallotta, V.; Chiantera, V.; Costantini, B.; Margariti, P.A.; Gueli Alletti, S.; Cosentino, F.; et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPIN trial): Final analysis of peri-operative outcome. *Eur. J. Cancer* 2016, 59, 22–33. [CrossRef]

32. da Costa Miranda, V.; de Souza Fêde, Â.B.; Dos Anjos, C.H.; da Silva, J.R.; Sanchez, F.B.; da Silva Bessa, L.R.; de Paula Carvalho, J.; Filho, E.A.; de Freitas, D.; Del Pilar Estevez Diz, M. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness. *Gynecol. Oncol.* 2014, 132, 287–291. [CrossRef]

33. Hou, J.Y.; Kelly, M.G.; Yu, H.; McAlpine, J.N.; Azodi, M.; Rutherford, T.J.; Schwartz, P.E. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. *Gynecol. Oncol.* 2007, 105, 211–217. [CrossRef]

34. O’Shea, A.; McCool, K.; Harrison, R.; Sampene, E.; Connor, J.; Barroilhet, L. Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer. *Gynecol. Oncol.* 2018, 150, 19–22. [CrossRef] [PubMed]
35. Meyer, L.A.; He, W.; Sun, C.C.; Zhao, H.; Wright, A.A.; Suidan, R.S.; Dottino, J.; Alejandro Rauh-Hain, J.; Lu, K.H.; Giordano, S.H. Neoadjuvant chemotherapy in elderly women with ovarian cancer: rates of use and effectiveness. *Gynecol. Oncol.* **2018**, *150*, 451–459. [CrossRef] [PubMed]

36. Orr, B.; Edwards, R.P. Diagnosis and treatment of ovarian cancer. *Hematol. Oncol. Clin. North Am.* **2018**, *32*, 943–964. [CrossRef] [PubMed]

37. Amir, M.; Shabot, M.M.; Karlan, B.Y. Surgical intensive care unit care after ovarian cancer surgery: an analysis of indications. *Am. J. Obstet. Gynecol.* **1997**, *176*, 1389–1393. [CrossRef] [PubMed]

38. Diaz-Montes, T.P.; Zahurak, M.L.; Bristow, R.E. Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer. *Gynecol. Oncol.* **2007**, *107*, 464–468. [CrossRef] [PubMed]

39. Pepin, K.; Bregar, A.; Davis, M.; Melamed, A.; Hinchcliff, E.; Gockley, A.; Horowitz, N.; Del Carmen, M.G. Intensive care admission among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery. *Gynecol. Oncol.* **2017**, *147*, 612–616. [CrossRef] [PubMed]

40. Birkmeyer, J.D.; Dimick, J.B.; Birkmeyer, N.J. Measuring the quality of surgical care: structure process, or outcomes? *J. Am. Coll. Surg.* **2004**, *198*, 626–632. [CrossRef] [PubMed]

41. Helman, S.N.; Brant, J.A.; Moubayed, S.P.; Newman, J.G.; Cannady, S.B.; Chai, R.L. Predictors of Length of Stay, Reoperation, and Readmission Following Total Laryngectomy. *Laryngoscope* **2017**, *127*, 1339–1344. [CrossRef]

42. American Hospital—Directory Medicare Inpatient Prospective Payment System. Available online: [https://www.ahd.com/ip_ipps08.html](https://www.ahd.com/ip_ipps08.html) (accessed on 12 February 2019).

43. Mohan, A. Length of Stay Trending Up: What Next?—Part I. Available online: [https://thehospitalleader.org/length-of-stay-trending-up-what-next-part-i/](https://thehospitalleader.org/length-of-stay-trending-up-what-next-part-i/) (accessed on 12 February 2019).

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).